MDM2 and breast carcinoma: While GATA3 has not been pursued as a direct therapeutic target, data suggest its potential indirect druggability in GATA3mut HR + breast cancer via inhibition of MDM2 (mouse double minute 2), an E3 ubiquitin-protein ligase that targets p53 for degradation [31].